EPS for Omeros (OMER) Expected At $-0.16; Novavax, Inc. (NVAX) Covered By 4 Bulls

February 24, 2018 - By Lawrence Diaz

Analysts expect Omeros Corporation (NASDAQ:OMER) to report $-0.16 EPS on March, 15.They anticipate $0.04 EPS change or 20.00% from last quarter’s $-0.2 EPS. After having $-0.07 EPS previously, Omeros Corporation’s analysts see 128.57% EPS growth. The stock increased 11.11% or $1 during the last trading session, reaching $10. About 1.63 million shares traded or 89.65% up from the average. Omeros Corporation (NASDAQ:OMER) has risen 42.59% since February 24, 2017 and is uptrending. It has outperformed by 25.89% the S&P500.

Among 12 analysts covering Novavax (NASDAQ:NVAX), 4 have Buy rating, 0 Sell and 8 Hold. Therefore 33% are positive. Novavax had 27 analyst reports since August 11, 2015 according to SRatingsIntel. The stock has “Neutral” rating by Wedbush on Friday, September 16. The stock of Novavax, Inc. (NASDAQ:NVAX) has “Hold” rating given on Friday, July 21 by Cantor Fitzgerald. Citigroup maintained it with “Neutral” rating and $1.50 target in Monday, September 19 report. The stock of Novavax, Inc. (NASDAQ:NVAX) has “Hold” rating given on Wednesday, November 8 by Cantor Fitzgerald. On Wednesday, August 9 the stock rating was upgraded by Ladenburg Thalmann to “Buy”. Chardan Capital Markets maintained the stock with “Neutral” rating in Tuesday, September 20 report. The stock has “Neutral” rating by JP Morgan on Friday, September 16. Piper Jaffray maintained it with “Overweight” rating and $17 target in Tuesday, August 11 report. On Tuesday, December 19 the stock rating was downgraded by Citigroup to “Neutral”. The stock of Novavax, Inc. (NASDAQ:NVAX) earned “Hold” rating by Cantor Fitzgerald on Thursday, August 10. See Novavax, Inc. (NASDAQ:NVAX) latest ratings:

21/02/2018 Broker: Citigroup Old Rating: Neutral New Rating: Neutral Old Target: $2 New Target: $2.75 Maintain
11/01/2018 Broker: FBR Capital Rating: Buy New Target: $10.0 Maintain
11/01/2018 Broker: Ladenburg Rating: Buy New Target: $2.5 Maintain
05/01/2018 Broker: B. Riley & Co Rating: Buy New Target: $2.25 Initiates Coverage On
05/01/2018 Broker: FBR Capital Rating: Buy New Target: $2.25
19/12/2017 Broker: Citigroup Old Rating: Buy New Rating: Neutral Downgrade
14/11/2017 Broker: Cantor Fitzgerald Rating: Hold New Target: $2.0 Maintain
08/11/2017 Broker: Cantor Fitzgerald Rating: Hold New Target: $2.0 Maintain
31/10/2017 Broker: Citigroup Old Rating: Neutral New Rating: Buy Upgrade
06/10/2017 Broker: Seaport Global Rating: Neutral Initiates Coverage On

Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company has market cap of $480.04 million. The firm markets OMIDRIA for use during cataract surgery or intraocular lens replacement. It currently has negative earnings. The Company’s clinical programs include OMS721 that is in Phase III clinical trial for the treatment of atypical hemolytic uremic syndrome; and in Phase II clinical trial to treat thrombotic microangiopathies, IgA nephropathy, and other renal diseases.

Investors sentiment increased to 2.86 in 2017 Q3. Its up 1.59, from 1.27 in 2017Q2. It increased, as 10 investors sold Omeros Corporation shares while 11 reduced holdings. 22 funds opened positions while 38 raised stakes. 22.04 million shares or 15.32% more from 19.11 million shares in 2017Q2 were reported. State Board Of Administration Of Florida Retirement Systems invested in 30,737 shares. Citadel Advsrs Lc invested in 65,802 shares. Group Inc One Trading L P invested in 0.02% or 80,014 shares. California Public Employees Retirement System accumulated 54,400 shares. Moreover, Blair William And Co Il has 0% invested in Omeros Corporation (NASDAQ:OMER). Royal Bank & Trust Of Canada has invested 0% in Omeros Corporation (NASDAQ:OMER). Swiss Financial Bank holds 0% or 75,100 shares in its portfolio. Moreover, State Street has 0% invested in Omeros Corporation (NASDAQ:OMER). Vanguard Group Inc owns 2.01 million shares. Bank & Trust Of Montreal Can owns 45,563 shares. Great West Life Assurance Can owns 0% invested in Omeros Corporation (NASDAQ:OMER) for 3,347 shares. The Illinois-based Northern Corp has invested 0% in Omeros Corporation (NASDAQ:OMER). Cormorant Asset Limited Liability Co reported 1.70M shares. Davenport & Ltd Liability invested in 0.02% or 79,400 shares. Citigroup owns 40,576 shares for 0% of their portfolio.

Since January 3, 2018, it had 0 insider buys, and 2 insider sales for $1.36 million activity. JACOBSEN MICHAEL A had sold 1,020 shares worth $22,899. 62,528 shares were sold by Kelbon Marcia S., worth $1.34M on Wednesday, January 3.

Among 9 analysts covering Omeros (NASDAQ:OMER), 7 have Buy rating, 0 Sell and 2 Hold. Therefore 78% are positive. Omeros had 26 analyst reports since August 10, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Monday, August 31 by Needham. The firm earned “Buy” rating on Thursday, November 10 by Needham. Cantor Fitzgerald maintained it with “Hold” rating and $1500 target in Tuesday, June 13 report. The stock has “Buy” rating by H.C. Wainwright on Thursday, December 14. The rating was initiated by TH Capital with “Buy” on Monday, August 10. H.C. Wainwright maintained Omeros Corporation (NASDAQ:OMER) rating on Wednesday, November 29. H.C. Wainwright has “Buy” rating and $30.0 target. The rating was maintained by Maxim Group with “Buy” on Wednesday, August 2. Cowen & Co maintained Omeros Corporation (NASDAQ:OMER) on Tuesday, August 18 with “Outperform” rating. Cantor Fitzgerald downgraded Omeros Corporation (NASDAQ:OMER) rating on Thursday, May 11. Cantor Fitzgerald has “Neutral” rating and $15 target. Maxim Group maintained the stock with “Buy” rating in Tuesday, June 13 report.

The stock decreased 2.51% or $0.06 during the last trading session, reaching $2.33. About 9.54M shares traded. Novavax, Inc. (NASDAQ:NVAX) has declined 79.61% since February 24, 2017 and is downtrending. It has underperformed by 96.31% the S&P500.

Novavax, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of recombinant nanoparticle vaccines and adjuvants. The company has market cap of $753.12 million. The firm develops respiratory syncytial virus fusion protein nanoparticle vaccine candidate for infants via maternal immunization in Phase III development stage; older adults in Phase II development stage; and children six months to five years of age in Phase I development stage. It currently has negative earnings. It also develops Ebola GP vaccine in Phase 1 clinical trial; preclinical programs for Zika virus; and seasonal influenza and a combination respiratory vaccine candidate, as well as other infectious disease vaccine candidates.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>